Page 1

Novavax Investor Relations Novavax Announces Initial Omicron Cross - Reactivity Data from COVID 19 Vaccine Booster and Adolescent Studies - Two - dose primary regimen of NVX - CoV2373 demonstrated cross - reactive immune responses against Omicron ( B.1.1.529 ) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials , with a 9.3 - fold IgG rise and a 19.9 - fold ACE2 inhibition increase after booster dose - Immune responses in adolescents were 2- to 4 - fold higher than adults against broad array of variants of interest and variants of concern - Development of Omicron - specific vaccine on track for initiation of GMP manufacturing in early January - Company to host investor conference call today from 4:30 - 5:00 pm ET GAITHERSBURG , Md . , Dec. 22 , 2021 / PRNewswire / -- Novavax , Inc. ( Nasdaq : NVAX ) , a biotechnology company dedicated to developing and commercializing next - generation vaccines for serious infectious diseases , today announced initial data evaluating the immune response of its COVID - 19 vaccine , NVX CoV2373 , against the Omicron variant as well as additional data from its ongoing Phase 2 boost study . New results demonstrate broad cross - reactivity against Omicron and other circulating variants from a primary 2 dose regimen , with responses that increased following a third dose at six months . Immune responses included the following : • Anti - spike IgG titers after Dose 3 increased 5.4 - fold ( prototype ) to 9.3 - fold ( Omicron ) from peak responses seen after 2 - dose primary vaccination . o This represents a 61.1 - fold ( prototype ) and a 73.5 - fold ( Omicron ) increase from prior to the Dose 3 boost . ACE2 - inhibition titers increased 6 - fold ( prototype ) to 19.9 - fold ( Omicron ) compared to peak responses following 2 - dose primary series , representing a 54.4 - fold ( prototype ) , a 24.4 - fold ( Delta ) and a 36.3 fold ( Omicron ) increase from prior to the booster . • Wild - type neutralization responses were observed after 2 doses for prototype , Delta and Omicron . Significant increases were observed after boosting , with titers for Delta and Omicron comparable to levels associated with protection in U.S. and Mexico and U.K. Phase 3 studies . o After 2 doses , Omicron wild - type neutralization was < 4 - fold lower than prototype , suggesting that both a booster dose as well as an Omicron - specific vaccine may be beneficial . Further , data from the pediatric expansion of Novavax ' PREVENT - 19 Phase 3 trial in the U.S. and Mexico